Market News

Ghost Tree Capital Has Cut Stake in Sage Therapeutics (Put) (SAGE) by $17.43 Million as Share Price Declined; As Cbre Group (CBG) Market Value Rose, Shareholder Hahn Capital Management Has Decreased Holding

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

Ken Greenberg decreased its stake in Sage Therapeutics Inc (Put) (SAGE) by 70.87% based on its latest 2017Q4 regulatory filing with the SEC. Ghost Tree Capital Llc sold 106,300 shares as the company’s stock declined 6.84% with the market. The hedge fund run by Ken Greenberg held 43,700 shares of the health care company at the end of 2017Q4, valued at $7.20 million, down from 150,000 at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Sage Therapeutics Inc (Put) for a number of months, seems to be less bullish one the $6.59B market cap company. The stock decreased 2.68% or $3.96 during the last trading session, reaching $144.05. About 266,256 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since April 23, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

Hahn Capital Management Llc decreased its stake in Cbre Group (CBG) by 1.55% based on its latest 2017Q4 regulatory filing with the SEC. Hahn Capital Management Llc sold 18,177 shares as the company’s stock rose 11.11% while stock markets declined. The institutional investor held 1.15M shares of the finance company at the end of 2017Q4, valued at $49.92B, down from 1.17M at the end of the previous reported quarter. Hahn Capital Management Llc who had been investing in Cbre Group for a number of months, seems to be less bullish one the $ market cap company. The stock decreased 0.23% or $0.11 during the last trading session, reaching $47.31. About 1.40M shares traded or Infinity% up from the average. CBRE Group Inc Class A (NYSE:CBG) has risen 31.31% since April 23, 2017 and is uptrending. It has outperformed by 19.76% the S&P500.

Investors sentiment increased to 1.24 in Q4 2017. Its up 0.28, from 0.96 in 2017Q3. It is positive, as 28 investors sold CBG shares while 159 reduced holdings. 78 funds opened positions while 154 raised stakes. 308.33 million shares or 1.51% less from 313.05 million shares in 2017Q3 were reported. Rbf Capital invested in 5,000 shares or 0.02% of the stock. Financial Bank Of Montreal Can holds 0.02% or 430,099 shares. Twin Tree Management Lp owns 17,435 shares. Raymond James And Associates reported 105,467 shares stake. Advsr Asset Mngmt Incorporated holds 0.11% or 152,715 shares in its portfolio. Shell Asset Management holds 17,729 shares or 0.02% of its portfolio. 172,804 are held by Nordea Inv Ab. Amalgamated Bancorporation holds 0.04% or 37,894 shares. Elk Creek Prtn Llc holds 5,419 shares. Us National Bank De holds 0.01% of its portfolio in CBRE Group Inc Class A (NYSE:CBG) for 70,196 shares. Laurion Mgmt Lp owns 718,712 shares. Fukoku Mutual Life Ins invested 0.04% in CBRE Group Inc Class A (NYSE:CBG). Ameriprise Financial Inc holds 0% in CBRE Group Inc Class A (NYSE:CBG) or 244,385 shares. Gyroscope Capital Mgmt Group Ltd Com stated it has 0.12% of its portfolio in CBRE Group Inc Class A (NYSE:CBG). Advisory Svcs Net Ltd Liability Corp has 3,977 shares.

Among 13 analysts covering CBRE Group (NYSE:CBG), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. CBRE Group had 30 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Conviction-Buy” rating given on Wednesday, August 12 by Goldman Sachs. Wedbush initiated it with “Outperform” rating and $35 target in Thursday, October 6 report. Keefe Bruyette & Woods maintained CBRE Group Inc Class A (NYSE:CBG) on Friday, February 9 with “Hold” rating. Barclays Capital maintained the shares of CBG in report on Tuesday, August 15 with “Overweight” rating. On Wednesday, January 24 the stock rating was downgraded by JMP Securities to “Market Perform”. On Monday, May 29 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. The rating was maintained by Keefe Bruyette & Woods with “Hold” on Thursday, July 20. On Wednesday, July 26 the stock rating was initiated by UBS with “Hold”. The stock of CBRE Group Inc Class A (NYSE:CBG) earned “Hold” rating by Keefe Bruyette & Woods on Thursday, December 21. The firm has “Buy” rating given on Tuesday, February 6 by Raymond James.

Since December 11, 2017, it had 0 buys, and 10 sales for $13.70 million activity. Frese Calvin W Jr sold $283,538 worth of stock or 6,033 shares. $866,400 worth of CBRE Group Inc Class A (NYSE:CBG) was sold by KIRK J. CHRISTOPHER. On Friday, February 9 the insider SULENTIC ROBERT E sold $1.70 million. 50,000 CBRE Group Inc Class A (NYSE:CBG) shares with value of $2.24M were sold by MALEK FREDERIC V. CONCANNON WILLIAM F had sold 29,483 shares worth $1.41 million on Monday, March 12. GROCH JAMES R sold 50,000 shares worth $2.25M.

Since December 14, 2017, it had 0 insider purchases, and 4 sales for $37.32 million activity. STARR KEVIN P sold 59,000 shares worth $9.96M. $7.80M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by Kanes Stephen on Wednesday, January 10. On Thursday, December 14 the insider Robichaud Albert sold $9.57M.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on May, 8. They expect $-1.85 earnings per share, down 21.71% or $0.33 from last year’s $-1.52 per share. After $-1.75 actual earnings per share reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.71% negative EPS growth.

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 56 analyst reports since September 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Monday, March 26. SunTrust maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, December 7 with “Buy” rating. The rating was maintained by BMO Capital Markets with “Outperform” on Friday, November 17. The company was initiated on Tuesday, May 24 by Chardan Capital Markets. Chardan Capital Markets upgraded the stock to “Buy” rating in Friday, November 10 report. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Wednesday, January 31 by BMO Capital Markets. The rating was maintained by BMO Capital Markets with “Outperform” on Thursday, September 14. Chardan Capital Markets upgraded the shares of SAGE in report on Thursday, December 7 to “Buy” rating. Raymond James upgraded Sage Therapeutics, Inc. (NASDAQ:SAGE) on Wednesday, December 14 to “Strong Buy” rating. The company was maintained on Thursday, November 9 by RBC Capital Markets.

Investors sentiment increased to 1.49 in 2017 Q4. Its up 0.28, from 1.21 in 2017Q3. It is positive, as 27 investors sold SAGE shares while 56 reduced holdings. 63 funds opened positions while 61 raised stakes. 41.45 million shares or 7.53% more from 38.55 million shares in 2017Q3 were reported. Smith Asset Mngmt Grp Inc Lp accumulated 6,840 shares. State Street holds 0.01% or 1.12M shares in its portfolio. Jabre Capital Ptnrs accumulated 0.06% or 1,900 shares. Citigroup has 0.01% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). First Republic Investment Inc owns 2,942 shares. Victory Cap Mngmt reported 281,930 shares or 0.1% of all its holdings. Pnc Fincl Svcs Group has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Highbridge Lc invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Fund Sa holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 3,065 shares. 17,000 were reported by Hbk Invests Ltd Partnership. Highland Mgmt Ltd Partnership holds 0.11% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 14,000 shares. Asset Management Inc reported 1,437 shares. Raymond James Associate holds 14,581 shares. 9,589 are owned by Driehaus Capital Management Ltd Liability. Wellington Mgmt Gru Ltd Liability Partnership stated it has 2.07M shares.

Ghost Tree Capital Llc, which manages about $426.44M US Long portfolio, upped its stake in Aimmune Therapeutics Inc by 8,200 shares to 158,200 shares, valued at $5.98 million in 2017Q4, according to the filing. It also increased its holding in Viewray Inc by 200,000 shares in the quarter, for a total of 900,000 shares, and has risen its stake in Global Blood Therapeutics In.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *